The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Baity Glenn since 2012.
The trader's CIK number is 1487100.
At the time of the last reporting, Baity Glenn was the VP AND GC of Acadia Pharmaceuticals Inc. (stock ticker symbol ACAD).
Also see all insider trading activities at Acadia Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | ACAD | 0 | $0 | 110,879 | $3,424,149 | 124,500 | $271,409 |
| 2017 | ACAD | 0 | $0 | 175,772 | $6,295,833 | 168,365 | $371,357 |
| 2016 | ACAD | 0 | $0 | 46,000 | $1,465,192 | 60,135 | $178,050 |
| 2014 | ACAD | 0 | $0 | 42,000 | $1,271,718 | 50,000 | $271,540 |
| 2013 | ACAD | 0 | $0 | 133,163 | $1,602,094 | 120,000 | $188,080 |
| 2012 | ACAD | 0 | $0 | 20,602 | $124,849 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-01-29 | ACAD | Sale | 36,558 | 32.39 | 1,184,040 |
| 2018-01-10 | ACAD | Option Ex | 50,179 | 2.18 | 109,390 |
| 2018-01-02 | ACAD | Option Ex | 74,321 | 2.18 | 162,019 |
| 2018-01-02 | ACAD | Sale | 74,321 | 30.14 | 2,240,109 |
| 2017-10-05 | ACAD | Sale | 37,500 | 40.91 | 1,534,050 |
| 2017-10-05 | ACAD | Option Ex | 28,500 | 1.93 | 55,090 |
| 2017-10-04 | ACAD | Option Ex | 11,000 | 1.90 | 20,900 |
| 2017-08-30 | ACAD | Option Ex | 16,507 | 1.62 | 26,741 |
| 2017-08-30 | ACAD | Sale | 26,507 | 34.87 | 924,325 |
| 2017-08-09 | ACAD | Option Ex | 14,322 | 1.58 | 22,700 |
| 2017-08-09 | ACAD | Sale | 14,322 | 34.88 | 499,537 |
| 2017-08-04 | ACAD | Option Ex | 6,500 | 1.62 | 10,530 |
| 2017-07-20 | ACAD | Sale | 38,097 | 30.00 | 1,142,910 |
| 2017-07-20 | ACAD | Option Ex | 28,097 | 1.62 | 45,517 |
| 2017-06-22 | ACAD | Option Ex | 1,903 | 1.62 | 3,082 |
| 2017-06-22 | ACAD | Sale | 1,903 | 30.00 | 57,090 |
| 2017-05-15 | ACAD | Option Ex | 14,093 | 1.62 | 22,830 |
| 2017-02-14 | ACAD | Option Ex | 26,365 | 4.98 | 131,297 |
| 2017-02-14 | ACAD | Sale | 26,365 | 39.66 | 1,045,530 |
| 2017-02-01 | ACAD | Sale | 31,078 | 35.15 | 1,092,391 |
| 2017-02-01 | ACAD | Option Ex | 21,078 | 1.55 | 32,670 |
| 2016-12-27 | ACAD | Option Ex | 9,800 | 1.55 | 15,190 |
| 2016-12-28 | ACAD | Option Ex | 5,500 | 1.62 | 8,910 |
| 2016-12-27 | ACAD | Sale | 9,800 | 30.46 | 298,478 |
| 2016-12-19 | ACAD | Option Ex | 8,635 | 1.64 | 14,161 |
| 2016-12-20 | ACAD | Option Ex | 10,000 | 1.55 | 15,500 |
| 2016-12-20 | ACAD | Sale | 10,000 | 30.00 | 300,000 |
| 2016-11-10 | ACAD | Option Ex | 10,200 | 1.55 | 15,810 |
| 2016-11-10 | ACAD | Sale | 10,200 | 30.07 | 306,683 |
| 2016-07-11 | ACAD | Option Ex | 4,057 | 6.78 | 27,506 |
| 2016-07-12 | ACAD | Option Ex | 11,943 | 6.78 | 80,973 |
| 2016-07-11 | ACAD | Sale | 4,057 | 35.00 | 142,003 |
| 2016-07-12 | ACAD | Sale | 11,943 | 35.00 | 418,028 |
| 2014-12-09 | ACAD | Option Ex | 8,000 | 1.55 | 12,400 |
| 2014-02-26 | ACAD | Option Ex | 42,000 | 6.17 | 259,140 |
| 2014-02-26 | ACAD | Sale | 42,000 | 30.28 | 1,271,718 |
| 2013-04-22 | ACAD | Option Ex | 10,000 | 1.62 | 16,200 |
| 2013-04-22 | ACAD | Sale | 10,000 | 13.15 | 131,490 |
| 2013-04-16 | ACAD | Option Ex | 20,000 | 1.55 | 31,000 |
| 2013-04-15 | ACAD | Option Ex | 20,000 | 1.55 | 31,000 |
| 2013-04-17 | ACAD | Sale | 10,000 | 12.26 | 122,600 |
| 2013-04-16 | ACAD | Sale | 20,000 | 12.30 | 246,000 |
| 2013-04-17 | ACAD | Option Ex | 10,000 | 1.55 | 15,500 |
| 2013-04-15 | ACAD | Sale | 20,000 | 12.50 | 250,000 |
| 2013-04-12 | ACAD | Sale | 30,000 | 12.87 | 386,100 |
| 2013-04-11 | ACAD | Sale | 30,000 | 12.02 | 360,600 |
| 2013-04-12 | ACAD | Option Ex | 30,000 | 1.57 | 47,190 |
| 2013-04-11 | ACAD | Option Ex | 30,000 | 1.57 | 47,190 |
| 2013-04-02 | ACAD | Sale | 13,163 | 8.00 | 105,304 |
| 2012-11-27 | ACAD | Sale | 16,206 | 6.28 | 101,757 |
| 2012-11-28 | ACAD | Sale | 4,396 | 5.25 | 23,092 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Baity Glenn (VP AND GC of Acadia Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.